Compromised Outcomes in Stage IV Non-Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data.
Jeffrey A ScottJochen K LennerzMelissa Lynne JohnsonLucio N GordanRobert H DumanoisLuca QuagliataLauren L RitterhouseFederico CappuzzoBrandon WangMei XueAnupama VasudevanPrateesh VarugheseVarun VaidyaMike GartNatalie DorrowHinco J GiermanRushir J ChoksiPublished in: JCO oncology practice (2023)
For patients harboring AODs in advanced NSCLC, initial treatment before receipt of genomic test results yields significantly inferior outcomes and should be avoided. Molecular profiling panels with rapid turnaround times are essential to optimize patient outcomes and should be standard of care.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- small cell lung cancer
- palliative care
- peritoneal dialysis
- type diabetes
- single cell
- machine learning
- quality improvement
- gene expression
- adipose tissue
- advanced non small cell lung cancer
- deep learning
- genome wide
- replacement therapy